Cargando…

Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights

Cell state is controlled by master transcription factors (mTFs) that determine the cellular gene expression program. Cancer cells acquire dysregulated gene expression programs by mutational and non-mutational processes. Intratumoral heterogeneity can result from cells displaying distinct mTF-regulat...

Descripción completa

Detalles Bibliográficos
Autores principales: Shendy, Noha A.M., Zimmerman, Mark W., Abraham, Brian J., Durbin, Adam D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133465/
https://www.ncbi.nlm.nih.gov/pubmed/35584622
http://dx.doi.org/10.1016/j.xcrm.2022.100632
_version_ 1784713574638157824
author Shendy, Noha A.M.
Zimmerman, Mark W.
Abraham, Brian J.
Durbin, Adam D.
author_facet Shendy, Noha A.M.
Zimmerman, Mark W.
Abraham, Brian J.
Durbin, Adam D.
author_sort Shendy, Noha A.M.
collection PubMed
description Cell state is controlled by master transcription factors (mTFs) that determine the cellular gene expression program. Cancer cells acquire dysregulated gene expression programs by mutational and non-mutational processes. Intratumoral heterogeneity can result from cells displaying distinct mTF-regulated cell states, which co-exist within the tumor. One archetypal tumor associated with transcriptionally regulated heterogeneity is high-risk neuroblastoma (NB). Patients with NB have poor overall survival despite intensive therapies, and relapsed patients are commonly refractory to treatment. The cellular populations that comprise NB are marked by different cohorts of mTFs and differential sensitivity to conventional therapies. Recent studies have highlighted mechanisms by which NB cells dynamically shift the cell state with treatment, revealing new opportunities to control the cellular response to treatment by manipulating cell-state-defining transcriptional programs. Here, we review recent advances in understanding transcriptionally defined cancer heterogeneity. We offer challenges to the field to encourage translation of basic science into clinical benefit.
format Online
Article
Text
id pubmed-9133465
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-91334652022-05-27 Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights Shendy, Noha A.M. Zimmerman, Mark W. Abraham, Brian J. Durbin, Adam D. Cell Rep Med Review Cell state is controlled by master transcription factors (mTFs) that determine the cellular gene expression program. Cancer cells acquire dysregulated gene expression programs by mutational and non-mutational processes. Intratumoral heterogeneity can result from cells displaying distinct mTF-regulated cell states, which co-exist within the tumor. One archetypal tumor associated with transcriptionally regulated heterogeneity is high-risk neuroblastoma (NB). Patients with NB have poor overall survival despite intensive therapies, and relapsed patients are commonly refractory to treatment. The cellular populations that comprise NB are marked by different cohorts of mTFs and differential sensitivity to conventional therapies. Recent studies have highlighted mechanisms by which NB cells dynamically shift the cell state with treatment, revealing new opportunities to control the cellular response to treatment by manipulating cell-state-defining transcriptional programs. Here, we review recent advances in understanding transcriptionally defined cancer heterogeneity. We offer challenges to the field to encourage translation of basic science into clinical benefit. Elsevier 2022-05-17 /pmc/articles/PMC9133465/ /pubmed/35584622 http://dx.doi.org/10.1016/j.xcrm.2022.100632 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Shendy, Noha A.M.
Zimmerman, Mark W.
Abraham, Brian J.
Durbin, Adam D.
Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights
title Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights
title_full Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights
title_fullStr Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights
title_full_unstemmed Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights
title_short Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights
title_sort intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133465/
https://www.ncbi.nlm.nih.gov/pubmed/35584622
http://dx.doi.org/10.1016/j.xcrm.2022.100632
work_keys_str_mv AT shendynohaam intrinsictranscriptionalheterogeneityinneuroblastomaguidesmechanisticandtherapeuticinsights
AT zimmermanmarkw intrinsictranscriptionalheterogeneityinneuroblastomaguidesmechanisticandtherapeuticinsights
AT abrahambrianj intrinsictranscriptionalheterogeneityinneuroblastomaguidesmechanisticandtherapeuticinsights
AT durbinadamd intrinsictranscriptionalheterogeneityinneuroblastomaguidesmechanisticandtherapeuticinsights